Green VC shoots in Poland's nascent innovation economy
This article was originally published in Scrip
With Poland's first ever dedicated life science venture capital (VC) fund having just announced its first closing at $42m, there are promising early signs that the country could be stepping up in the space. Kreske Nickelsen, a veteran of 3i Group and Aescap, is one of the managers of the new Joint Polish Investment Fund (JPIF). She told Scrip about the backdrop to the fund's launch, and why Poland may be one to watch.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.